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Objective. To determine the role of imaging-cytology correlation in reducing false negative results of fine-needle aspiration (FNA)
at thyroid nodules. Methods. This retrospective study included 667 nodules 1 cm or larger in 649 patients diagnosed as benign at
initial cytologic evaluation and that underwent follow-up ultrasound (US) or FNA following a radiologist’s opinion on concordance
between imaging and cytologic results. We compared the risk of malignancy of nodules classified into subgroups according to the
initial US features and imaging-cytology correlation. Results. Among included nodules, 11 nodules were proven to be malignant
(1.6%) in follow-up FNA or surgery.Themalignancy rate was higher in nodules with suspicious US features (11.4%) than in nodules
without suspicious US features (0.5%, 𝑃 < 0.001). When a thyroid nodule had discordant US findings on image review after having
benign FNA results, malignancy rate increased to 23.3%, significantly higher than that of nodules with suspicious US features
(𝑃 < 0.001). However, no significant difference was found in the risk of malignancy between the nodules without suspicious US
features (0.5%) and imaging-cytology concordant nodules (0.6%, 𝑃 = 0.438). Conclusions. Repeat FNA can be effectively limited to
patients with cytologically benign thyroid nodules showing discordance in imaging-cytology correlation after initial biopsy, which
reduces unnecessary repeat aspirations.
1. Introduction
Fine-needle aspiration (FNA) is the standard method used
to determine treatment plans for thyroid nodules. Based on
the Bethesda system, the most generally accepted system for
reporting thyroid cytology, the “benign” category implies a
less than 3% risk of malignancy [1]. Follow-up ultrasound
(US) is recommended when the nodule has “benign” cyto-
logic result [2]. Repeat FNA is recommended when a nodule
shows significant growth or morphologic transformation
with “suspicious” US features on follow-up [3, 4]. However,
the practical risk of malignancy in nodules with benign
cytology varies in each institute, ranging from 2% to 18%
[5], and it has even been reported to have gone up to 62%
[6].Therefore, some investigators recommend routine repeat
FNA for thyroid nodules with benign cytology [7, 8].
Considering cost-effectiveness and diagnostic value,
repeat FNA has been considered when the nodule shows any
suspicious feature on the initial US [9, 10]. However, known
US features associated with malignancy show an extremely
variable probability of malignancy [11]. Microcalcifications,
marked hypoechogenicity, and irregular or spiculatedmargin
show a high risk of malignancy, while solid composition and
hypoechogenicity show a relatively low positive predictive
value (PPV) [11–13]. Based on these results, each suspicious
US feature may not be considered as an equal risk factor for
malignancy.
Radiologists specialized in breast imaging have been
confronted with the same problem in the core needle biopsy
of a breast lesion. Correlation of pathologic results with
sonographic findings has been used in some institutions to
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3119 thyroid nodules in 2866 patients undergoing FNA
3076 thyroid nodules in 2829 patients with 
benign cytologic results
43 thyroid nodules in 42 patients with history of prior 
FNA on the same nodule
1201 thyroid nodules in 1169 patients
1914 thyroid nodules in 1819 patients
713 thyroid nodules in 694 patients smaller than 1 cm
781 thyroid nodules in 761 patients
667 thyroid nodules in 649 patients
420 thyroid nodules in 413 patients whose surgical
pathology, follow-up FNA, or follow-up US findings
were not available
1162 thyroid nodules in 1087 patients whose FNA
results were not “benign”
114 thyroid nodules in 112 patients without additional
radiologist’s report regarding imaging-cytologic
correlation
Figure 1: Flow chart of case enrollment.
verify that the lesion was adequately sampled. Discordant
benign breast nodules are recommended for rebiopsy to
confirm the diagnosis. This approach was suggested owing
to the wide range of false negative rates of this category [14].
Based on different malignancy rates of suspicious US features
in thyroid nodules and considering approaching steps in
management of breast lesions, we conjecture that an imaging-
cytology correlation can be a better diagnostic approach for
patient management than initial US features in a thyroid
nodule with benign cytology. Therefore, we investigated
the role of imaging-cytology correlation to reduce the false
negative rates of cytology at thyroid nodules as compared
with the use of initial US features.
2. Materials and Methods
2.1. Patients. The Institutional Review Board of the Sev-
erance Hospital approved of this retrospective study and
required neither patient approval nor informed consent for
our review of patients’ images and records. However, written
informed consents were obtained from all patients for US-
guided FNAs (US-FNAs) prior to each procedure as a daily
practice. Our institutional registry for the thyroid nodule
was settled since 2006 including all patients with thyroid
nodules who underwent US examinations and US-FNAs at
our institution. From March 2006 to December 2006, 3119
consecutive thyroid nodules in 2866 patients underwent US-
FNAs. Among them, we included 667 nodules in 649 patients
(men, 83; women, 566), which fulfilled the following criteria:
(a) they had no history of prior FNA on the same nodule; (b)
they were reported as benign (category II) in the initial FNA.
Nodules reported as “nondiagnostic,” “atypia or follicular
lesions of undetermined significance,” “follicular neoplasmor
suspicious for a follicular neoplasm,” “suspicious for malig-
nancy,” and “malignant” were excluded; (c) they were equal
to or larger than 1 cm; (d) they underwent further evaluation
such as follow-up US, follow-up FNA, or thyroid surgery. In
nodules which had not underwent operation, determinative
cytologic reports (category II or category VI) on follow-up
US were used as standard reference. If a nodule decreased
in size on follow-up US, the nodule was also included as
a benign nodule; (e) there were available radiologic reports
that included an additional radiologist’s opinion about the
concordance or discordance between imaging and cytologic
results in postbiopsy correlation (Figure 1). Mean age of the
patients was 49.1 years (range, 13–87 years). Mean lesion
size of the thyroid nodules was 20.7mm (range, 10–70mm).
Median follow-up of 601 nodules in 584 patients which were
included based on followup FNA or US without surgical
pathology was 1509 days from the date of initial FNA to
the last followup (IQR, 1522 days; range, 172–2744 days).
The other nodules were included based on their surgical
pathology as a standard reference.
2.2. Imaging Methods and Analysis. All US examinations
were performed using a 7 to 15 MHz linear array transducer
(HDI 5000; Philips Medical Systems, Bothell, Wash) or a 5 to
12 MHz linear probe (iU22, Philips Medical Systems) by 1 of
5 board-certified radiologists with 1 to 12 years of experience
in thyroid imaging. All US-FNAs were performed by the
same radiologist who performed the US examinations. The
nodule size was defined as the largest diameter on US. US
features of all thyroid nodules that underwent US-FNAs were
prospectively recorded by the previously described methods
[19]. US features suspicious for malignancy were determined
using previously published criteria from our institution:
marked hypoechogenicity, microlobulated or irregular mar-
gin, microcalcifications, and taller than wider shape. When
overall echogenicity of a nodule was darker than that of
the surrounding strap muscle, it was defined as “marked
hypoechogenicity” to differentiate it from “hypoechogenic-
ity” based on the parenchymal echogenicity of the thyroid
gland. Microlobulated margin meant that a nodule hadmany
small lobular contours on the surface. Microcalcifications
were defined as tiny hyperechoic foci either with or without
acoustic shadowing. Only calcifications equal to or less than
1mm in diameter were indicated. If microcalcifications were
detected with macrocalcifications, the lesion was considered
to have microcalcifications as a worrisome finding. If hyper-
echoic foci accompanied comet-tail artifacts on conventional
US, they were considered as colloids [20]. An anteroposterior
to transverse dimension ratio greater than 1 was defined as
taller than wider shape.
2.3. US-Guided Fine-Needle Aspiration. US-FNAs were per-
formed on either thyroid nodules with suspicious assessment
or the largest nodule among nodules with probably benign
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assessment on US. If there were multiple nodules with
suspicious US findings in one patient or if the patient or
physician requested a biopsy of a benign-looking nodule
coexisting with a nodule showing suspicious US features,
FNAs were performed on multiple nodules in one patient.
A free-hand biopsy technique was used with either a 23-
gauge needle attached to a 20mL disposable plastic syringe
and an aspirator or a 23-gauge needle attached to a 2mL
disposable plastic syringe, depending on the performing
radiologist’s preference. Each lesion was aspirated at least
twice, and the aspirated materials were expelled onto a slide
and immediately placed in 95% alcohol for Papanicolaou
staining.The remainingmaterials were rinsedwith saline and
processed for cell blocking. The cytopathologist was not on
site during the biopsy. Five cytopathologists interpreted the
slides. Additional special staining was performed according
to the requirement of the cytopathologist. An inadequate
specimenwas defined as less than 6 groups of cells containing
more than 10 cells [3]. Adequate specimens were categorized
as benign, indeterminate, suspicious for malignancy, or
malignant samples.
2.4. Imaging-Cytology Correlation and Postaspiration Man-
agement. The radiologist who performed FNA routinely
reviewed the initial US images within a week of the FNA
after the cytologic results were reported. For benign cytologic
results, radiologists who performed the US-FNAs decided
and reported whether the cytology was concordant or
discordant with the imaging findings. As researchers at
our institution always try to assess lesions based on their
most worrisome finding, the saved images should represent
these worrisome US features. Image-cytology correlation
was done based on these images. The final conclusion was
not derived from the number of suspicious US features
but from the subjective decision made by the radiologist
who performed the US-FNA. In our institution, “concordant
lesions” included some nodules which had suspicious US
features on the initial US but were acceptable for the benign
cytology in postbiopsy image review as well as the nodules
without features suspicious for malignancy on the initial
US. Concordant benign thyroid nodules were recommended
for follow-up by US after one year. In contrast, “discordant
lesions” included nodules which were initially suspected for
malignancy on US and were still thought to be suspicious for
cancer even after obtaining benign cytology. Repeat FNAs
were usually recommended for discordant benign thyroid
nodules after 6–12 months [21]. Among the 667 nodules that
met all the inclusion criteria, 586 nodules (87.9%, 586 of
667) were reviewed by radiologists who had more than three
years of experience in thyroid imaging and FNA whereas
the remaining nodules were managed by less experienced
radiologist.
2.5. Statistical Analysis. We compared the clinical character-
istics of patients between benign and malignant nodules by
using the 𝜒2 test for categorical variables and independent
𝑡-test for continuous variables. We also compared the risk
of malignancy as well as the clinical characteristics between
concordant and discordant nodules by using 𝜒2 or Fisher’s
exact test for categorical variables and independent 𝑡-test
for continuous variables. The baseline characteristics were
also compared between patients with included and excluded
nodules among thyroid nodules equal to or larger than 1 cm
with the same methods.
The risk of malignancy was calculated for several sub-
groups classified according to initialUS features and imaging-
cytology concordance. Using the generalized estimating
equation, we compared the risk of malignancy in thyroid
nodules with initially benign cytologic results with those
of the remaining subgroups and also compared the risk of
malignancy of thyroid nodules among subgroups.
Significance was assumed when the two-sided 𝑃 value
was less than .05. Logistic regression analysis was performed
to assess the odds ratio for the risk of malignancy. Odds
ratios with relative 95% confidence intervals (CIs) were also
calculated. Statistical analysis was performed using commer-
cial statistical software (SAS version 9.1, SAS Inc., Cary, NC,
USA).
3. Results
Among 667 nodules with initially benign cytologic results,
656 nodules were benign (98.4%) and 11 nodules were
malignant (1.6%) based on cytopathology (Table 1).Themean
age of patients with malignant nodules was not significantly
different from that of patients with benign nodules (𝑃 =
0.277). Gender of patients was not associated with malig-
nancy (𝑃 = 0.734). The mean size of malignant nodules
(17.6 ± 12.5mm) was not significantly different from that of
benign nodules (20.7 ± 10.1mm, 𝑃 = 0.315). There were 70
nodules with initial suspicious US features and 597 nodules
without initial suspicious US features.The risk of malignancy
was higher in nodules with initial suspicious US features
(11.4%, 8 of 70) than in nodules without initial suspicious US
features (0.5%, 3 of 597; 𝑃 < 0.001, Table 1).
When reviewing US images after initial FNA results were
reported, 40 out of 70 nodules which had suspicious features
on initial US evaluation were finally concluded as concordant
with benign cytology (Figures 2 and 3).Therefore, in 667 nod-
ules with benign cytology, 637 nodules were concordant with
cytology, whereas 30 nodules were discordant with benign
cytology.The reasons that 40 nodules with revised radiologic
diagnosis after imaging-cytologic correlation were initially
classified as suspicious nodules were microcalcifications (𝑛 =
16), microlobulated or irregular margin (𝑛 = 9), taller than
wider shape (𝑛 = 3), or marked hypoechogenicity (𝑛 =
1) in order of frequency, respectively, and more than one
characteristic of the above features in 11 nodules. Between
the concordant and discordant group, gender of the patients
was not significantly different (𝑃 = 0.159). The patients
with discordant nodules were significantly older than other
patients with concordant nodules (53.5 ± 10.5 years versus
48.9 ± 12.0 years; 𝑃 = 0.038). The mean size of discordant
nodules was significantly smaller than that of concordant
nodules (16.0±6.6mmversus 20.9±10.2mm;𝑃 < 0.001).The
rate of malignancy was significantly higher in the discordant
group (23. 3%; 7 of 30) than in the concordant group (0.6%,
4 of 637; 𝑃 < 0.001).
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Table 1: Baseline characteristics of 667 thyroid nodules with benign cytology.
Reference standard Benign Malignant 𝑃 value
Number of nodules 656 11
Mean age (years)∗ 49.1 ± 12.0 53.0 ± 11.4 0.277
Gender 0.734
Male 82 (12.5) 1 (9.1)
Female 574 (87.5) 10 (90.9)
Mean nodule size (mm)∗ 20.7 ± 10.1 17.6 ± 12.5 0.315
US final assessment before FNA <0.001
Probably benign 594 (90.5) 3 (27.3)
Suspicious malignant 62 (9.5) 8 (72.7)
FNA: fine-needle aspiration.
Data in parentheses are percentages.
∗Data are the means ± standard deviations.
(a) (b)
Figure 2: Initially suspicious but concordant nodule after imaging-cytology correlation. US scans ((a) transverse; (b) longitudinal) in a 41-
year-old female without remarkable medical history show a 16mm sized predominantly solid mass (arrows) with microlobulated margin in
the lower pole of the right lobe of the thyroid gland. The nodule was taller than wider on transverse scan. The initial cytologic result was
adenomatous hyperplasia which was concordant with US findings considering relatively low PPV of these US finding in imaging-cytology
correlation after biopsy. A follow-up US was recommended and nodule size gradually decreased from 16mm to 13mm with decrease of the
cystic portion in follow-up US evaluations until July 2013 without any other significant changes in US features.
(a) (b)
Figure 3: Initially suspicious but concordant nodule after imaging-cytology correlation. US scans ((a) transverse; (b) longitudinal) in a 54-
year-old female without remarkable medical history show a 12mm sized solid mass (arrows) with internal echogenic foci in the lower pole
of the right lobe of the thyroid gland. The initial cytologic result was adenomatous hyperplasia which was concordant with US findings in
imaging-cytology correlation after biopsy. At the time of imaging-cytology correlation, the echogenic foci (arrowheads) were thought to be
related to colloids instead of microcalcifications from psammoma bodies. She underwent surgery (left total and right subtotal thyroidectomy)
due to papillary carcinoma in the contralateral lobe of the thyroid gland. The mass in the right lobe was finally confirmed as adenomatous
hyperplasia on pathology.
About 44.5% (534 of 1201) of 1 cm or larger nodules with
benign cytology in initial FNA were excluded because they
had neither standard reference, such as follow-up US, follow-
up FNA, or thyroid surgery, nor available radiologist’s addi-
tional reports regarding imaging-cytologic correlation. The
mean age of patients with included nodules was statistically
different from the other patients (49.1±12.0 versus 50.7±13.1
years; 𝑃 = 0.033). Patient gender (𝑃 = 0.392) and mean
nodule size (𝑃 = 0.601) were not significantly different
between included and excluded nodules. There were 60
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Table 2: Comparison of baseline characteristics of nodules according to inclusion criteria among 1 cm or larger 1201 thyroid nodules with
benign cytology.
Included nodules Excluded nodules 𝑃 value
Number of nodules 667 534
Mean age (years)∗ 49.1 ± 12.0 50.7 ± 13.1 0.033
Gender 0.392
Male 83 (12.4) 76 (14.2)
Female 584 (87.6) 458 (85.8)
Mean nodule size (mm)∗ 20.7 ± 10.1 21.0 ± 10.6 0.601
US final assessment 0.709
Probably benign 597 (89.5) 474 (88.8)
Suspicious malignant 70 (10.5) 60 (11.2)
Data in parentheses are percentages.
∗Data are the means ± standard deviations.
Table 3: Risk of malignancy according to initial US features and imaging-cytologic correlation in thyroid nodules with benign cytologic
results.
Number of
nodules
Number of
malignant
nodules
Risk of
malignancy (%)
Benign cytology alone 667 11 1.6 (0.8, 2.9)
Initial no suspicious US 597 3 0.5 (0.1, 1.5)
Initial suspicious US 70 8 11.4 (5.1, 21.3)
Concordant lesion to benign cytology in postbiopsy correlation 637 4 0.6 (0.2, 1.6)
Discordant lesion to benign cytology in postbiopsy correlation 30 7 23.3 (9.9, 42.3)
Data in parentheses are 95% confidence intervals.
nodules with suspicious findings in the initial US evaluation
of excluded nodules (11.2%, 60 of 534), and the proportion
was not significantly different from that of included nodules
(10.5%, 70 of 667; Table 2).
When comparing the risk of malignancy between benign
cytology alone and each subgroup by a combination of benign
cytology with initial US findings or postbiopsy concordance,
all combinations had significantly different risk values from
cytology alone (Table 3, Figure 4). Also, when comparing the
risk of malignancy between discordant lesions and lesions
with suspicious features on initial US, the former (23.3%, 7
of 30) was significantly higher than the latter (11.4%, 8 of 70).
However, there was no significant difference in the risk of
malignancy between concordant lesions (0.6%, 4 of 637) and
lesions without suspicious features on initial US (0.5%, 3 of
597; 𝑃 = 0.438) (Figure 4).
4. Discussion
Although FNA is a widely used tool for the diagnosis of
thyroid nodules, the most significant problem it has is
false negative results which bring out misses and delays in
treatment of the cancer [22]. Errors in cytologic reports have
arisen from the overinterpretation of nondiagnostic speci-
mens as diagnostic ones [23, 24]. Therefore, many reports
discussed the differentiation of a nondiagnostic specimen
from a diagnostic one in the cytologic interpretation of
thyroid FNA [1, 3]. Diagnostic errors of thyroid FNA can
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Figure 4: Comparison of malignancy rates in thyroid nodules
with benign cytology according to initial US features or imaging-
cytology concordance. Error bars for 95% confidence intervals. ∗𝑃
value < 0.001. †Concordant lesions include some nodules which
had suspicious US features on initial US but were acceptable for
benign cytology in postbiopsy image review as well as nodules
without suspicious US features on initial US. ‡Discordant lesions
include nodules which were initially suspected for malignancy on
US and were still regarded as suspicious even after obtaining benign
cytology.
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Table 4: Reported rate of malignancy in nodules with benign cytology according to US finding.
Total number
of nodules
Rate of malignancy (%) Suspicious US features
Overall Suspicious US No suspicious US
Kwak et al. [9] 1343 1.9 (26/1343) 20.4 (19/93) 0.6 (7/1250)
Marked hypoechogenicity,
microlobulated or irregular
margin, microcalcification, and
taller than wider shape
Koike et al. [15] 168 11.9 (20/168) 47.1 (8/17) 7.9 (12/151)
Ill-defined margin, irregular
shape, solid echo structure,
heterogeneous internal
echogenicity, hypoechogenicity,
presence of calcification, absence
of halo, and invasion of adjacent
organs
Lee et al. [16] 560 1.1 (6/560) 3.7 (4/108) 0.4 (2/452)
Marked hypoechogenicity,
microlobulated or irregular
margin, microcalcification, and
taller than wider shape
Maia et al. [17] 35 28.6 (10/35) 38.5 (5/13) 22.7 (5/22)
Hypoechogenicity,
microcalcification, border
irregularity, and central flow by
Doppler study
Choi et al. [18]∗ 700 1.7 (12/700) 4.7 (8/169) 0.8 (4/531)
Marked hypoechogenicity, not
well-defined margin,
microcalcifications, and taller
than wide shape
Data in parentheses are numbers used to calculate percentages.
∗Multicenter study from 7 university-affiliated hospitals.
also be caused by the mistakes of cytopathologists and
the inherent nature of thyroid nodules due to overlapping
cytologic criteria among hyperplastic adenomatoid nodule
in goiter, follicular adenoma, well-differentiated follicular
carcinoma, and follicular variant of papillary carcinoma [25].
Moreover, reported false negative rates are variable among
institutions and operators due to variable sampling skills
[5, 6].
Several guidelines recommend follow-up US in thyroid
nodules with benign cytology unless the nodule shows
significant growth or morphologic change in follow-up US
[1, 3, 4]. However, it has been argued that follow-up might
be not enough in some nodules because of the inevitable
false negative diagnosis and the possible risk of delayed
treatment [6, 22]. To reduce false negative results of thyroid
FNAs, there have been two suggested approaches; first,
routine repeat FNA in thyroid nodules with benign cytology
[26, 27] and, second, selective repeat FNA [8, 10, 28, 29].
In the aspect of cost-effectiveness, it is more rational to
consider performing follow-up FNA selectively for nodules
with a high-risk of malignancy rather than performing a total
inspection of cytologically benign nodules in initial FNA.
Based on several reports, the rate of malignancy in benign
thyroid nodules with suspicious US features was 3.7–47.1%
which was significantly higher than that of benign thyroid
nodules without suspicious US features (Table 4) [9, 15–18].
Although the US criteria applied to each study had subtle
differences, initial US features may be reliable factors in
determining whether to repeat FNA or not [17].
Going one step further from simply matching cytologic
results against imaging findings evaluated before biopsy,
the postbiopsy correlation of US features with cytologic
results could be an alternative in determining whether the
nodule should be reaspirated to confirm its cytology or not.
Imaging-pathologic correlation after biopsy has been found
to be useful in validating biopsy results of breast lesions,
and discordance has been suggested as an indication for
excision because of its higher upgrade rate than that of
concordant lesions [30–32]. However, there has been no
organized study that applies imaging-cytology correlation to
patient management and considers how to accept results of
postbiopsy correlation in regard to reducing false negative
diagnosis in thyroid nodules.
In this study, 1.6% of nodules with benign cytology in
initial FNA were finally proven to be malignant. As expected,
the malignancy rate of thyroid nodules (11.4%) with suspi-
cious features on initial US was significantly higher than that
of nodules (0.5%) without suspicious features on initial US,
and the malignancy rate of nodules (23.3%) with discordant
imaging findings was also significantly higher compared to
concordant nodules (0.6%) in postbiopsy imaging-cytologic
correlations. Furthermore, the rate of malignancy was higher
in the nodules showing imaging-cytology discordance com-
pared to nodules showing suspicious feature on the initial
US. However, there was no significant difference in the risk
of malignancy between concordant nodules in postbiopsy
correlation and nodules without suspicious features on ini-
tial US. This result lets us conclude that imaging-cytology
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correlation is a more effective approach than using initial
US features alone when deciding follow-up management in
patients with cytologically benign thyroid nodules without a
statistical increase in missing malignancy.
In this study, 40 of 70 nodules with suspicious features
on initial US were determined as concordant with benign
cytology after postbiopsy imaging-cytology correlation. This
change can be explained by the subjective nature of US
evaluation. Although many descriptions of each suspicious
US feature are present, interobserver and intraobserver vari-
ability still exist for the US assessment of thyroid nodules.
Among US characteristics, margin and calcification showed
relatively less consistency between observers [33] andnodules
in most patients whose radiologic assessments were changed
after obtaining benign cytology were initially assumed as
suspicious nodule due to calcification (16 of 40), margin
(9 of 40), or multiple features (11 of 40) including them
in our study. Also, there have been difficulties in deciding
whether a thyroid nodule shows echogenic spots on US.
Echogenic spots can be due to microcalcifications related to
cancer or crystals related to colloids [34]. Therefore, post-
biopsy imaging-cytology correlation can be a good diagnostic
approach in deciding whether to repeat FNA or not at a
thyroid nodule with benign cytology.
There were several limitations to this study. First, some
nodules were excluded in analysis despite having benign
cytologic results due to loss of follow-up and absence
of additional reports. Selection bias may be unavoidable.
However, the initial US assessment was not significantly
different between included nodules and excluded nodules
which were 1 cm or larger with benign cytology in the initial
FNA. Second, interobserver and intraobserver variability
among radiologists are possible in the interpretation of US
images and among cytologists, especially when reviewing
follicular lesions. Third, there might be a bias arising from
the postbiopsy review process itself whichwas based on saved
images instead of on a review in real-time US. Although
we always tried to save any images showing worrisome
US findings and the postbiopsy review was preferably done
within a week of biopsy by the performer, an observer bias
might not have been completely removed from the final
results. Fourth, suspicious US features such as calcification,
margin, vascularity, and echogenicity have been differently
applied to thyroid nodules by various guidelines and different
institutions. Therefore, the result of this study needs to be
validated in other institutions. Fifth, most (87.9%) of the
nodules in this study were reviewed by highly experienced
radiologists in thyroid imaging.Therefore, the resultsmay not
be reproducible in other institutions.
5. Conclusions
Repeat FNA can be effectively limited to patients with
cytologically benign thyroid nodules showing discordance
in imaging-cytology correlation, which reduces unnecessary
repeat aspirations as well as decreasing false negative results.
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